Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CGEN vs MCRB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CGEN Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

CGEN Overall Winner 6-Pillar Tally: CGEN 5 – 1 MCRB Matrix Metrics: CGEN 8 – 2 MCRB

As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Seres Therapeutics, Inc. (MCRB) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CGEN carries a Unified Composite Score of 47.1/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin), whereas MCRB carries 50.0/100 (HOLD) at $1.41 (10.8x Forward P/E, -3115.1% operating margin).

  • Composite vs. Pillar Nuance: While MCRB currently prints a higher short-term Unified Composite Score (50.0/100 HOLD vs. CGEN 47.1/100 HOLD), CGEN captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (41.3% vs. -3115.1% operating margin) and revenue trajectory (+102.1% vs. +68.9% YoY).
  • Technical & Structure Timing Caution: CGEN is currently in a Breakdown options structure phase (RSI 46.9); meanwhile MCRB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CGEN vs MCRB
CGEN NASDAQ Head-to-Head Winner
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.98% 1D
Market Cap $193.2M
TTM Revenue $76M
Forward P/E 12.4x
Beta / 30D Vol 1.44β · 62% Vol
Unified Composite Score
47.1 / 100 HOLD
Tech 44.0 Fund 52.0 Flow 54.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.9 · SMA20: $2.02 · SMA50: $2.18
MCRB NASDAQ
Seres Therapeutics, Inc.
Pharmaceutical Preparations
$1.41
+0.0% 1D
Market Cap $13.8M
TTM Revenue $2.1M
Forward P/E 10.8x
Beta / 30D Vol 0.68β · 92% Vol
Unified Composite Score
50.0 / 100 HOLD
Tech 60.0 Fund 57.0 Flow 66.0 Mom 63.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -30.7%), weak momentum, RSI 24
RSI-14: 23.8 · SMA20: $1.81 · SMA50: $2.79

6-Pillar Scorecard Institutional Category Breakdown (CGEN 5 – 1 MCRB)

Columns: Metric · CGEN · MCRB
1. Valuation Multiples CGEN
Forward P/E 12.4x 10.8x
Trailing P/E 5.2x 10.8x
PEG Ratio 1.29x N/M
EV / Revenue 2.5x 15.1x
2. Growth & Scale CGEN
Revenue Growth (YoY) +102.1% +68.9%
Earnings Growth (YoY) +0.0% -91.9%
TTM Revenue (USD) $76M $2.1M
Market Cap $193.2M $13.8M
3. Profitability & Quality CGEN
Gross Margin 86.2% N/A
Operating Margin 41.3% -3115.1%
Net Profit Margin 47.9% 0.0%
Return on Equity (ROE) 57.2% -144.3%
4. Balance Sheet & Cash Flow CGEN
Cash Generation (TTM) $32M EBITDA -$63M EBITDA
Cash Flow Margin 41.9% EBITDA Mgn N/A
Net Cash / Leverage $4.3M Net Cash $18M Net Debt (1.67x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MCRB
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 89.7% (57th %ile) 95.5% (22nd %ile)
Put/Call OI Skew N/A 104.33x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat CGEN
OpEx & R&D Intensity 44.9% of Rev ($34M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CGEN (8) vs MCRB (2)
Institutional Metric CGEN MCRB Criterion Row Edge
Market Capitalization
Scale
$193.2M $13.8M Larger Scale CGEN
Trailing P/E Ratio
Valuation
5.2x 10.8x Lower Multiple CGEN
Forward P/E Ratio
Valuation
12.4x 10.8x Lower Multiple MCRB
Revenue Growth (YoY)
Growth
+102.1% +68.9% Higher Growth CGEN
Operating Margin (TTM)
Profitability
41.3% -3115.1% Higher Margin CGEN
Net Profit Margin
Profitability
47.9% 0.0% Higher Margin CGEN
Return on Equity (ROE)
Capital Efficiency
57.2% -144.3% Higher ROE CGEN
52-Week Range Position
Momentum
33% ($1–$3) 0% ($1–$30) Stronger Trend CGEN
Beta / 30D Volatility
Risk Regime
1.44β · 62% Vol 0.68β · 92% Vol Lower Realized Risk CGEN
Unified Institutional Score
Composite Signal
47.1 / 100 (HOLD) 50.0 / 100 (HOLD) Higher Composite MCRB
Trailing 12M Revenue (USD)
Operating Scale
$76M $2.1M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
86.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.29x PEG · 2.5x EV/Rev N/M PEG · 15.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$32M EBITDA ($4.3M Net Cash) -$63M EBITDA ($18M Net Debt (1.67x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CGEN +44.28 pp
CGEN: +2.54% · MCRB: -41.74%
3M Horizon CGEN +52.66 pp
CGEN: -17.21% · MCRB: -69.87%
6M Horizon CGEN +55.04 pp
CGEN: -26.01% · MCRB: -81.05%
1Y Horizon CGEN +114.71 pp
CGEN: +23.17% · MCRB: -91.54%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CGEN Revenue MCRB Revenue CGEN Op. Margin MCRB Op. Margin Margin Leader
FY2018 $20M $30M -130.5% -372.6% CGEN
FY2019 N/A $30M N/A -264.4% MCRB
FY2020 $0M $10M -1574.8% -740.8% MCRB
FY2021 $10M $140M -584.6% -44.8% MCRB
FY2022 $10M $10M -471.7% -2524.0% CGEN
FY2023 $30M N/A -38.8% N/A CGEN
FY2024 $30M N/A -53.4% N/A CGEN
FY2025 $70M $0M 43.1% -11910.1% CGEN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CGEN BREAKDOWN
143d in phase · OBV NEUTRAL
Current IV 89.7%
IV Percentile 57th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MCRB BREAKDOWN
94d in phase · OBV DISTRIBUTION
Current IV 95.5%
IV Percentile 22nd %ile
Put/Call OI Skew 104.33x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact MCRB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CGEN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $193.2M market capitalization and 41.3% operating margin.
OpEx & R&D Reinvestment 44.9% of Rev ($34M)
90D Engineering Disclosures 0 Published
MCRB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $13.8M market capitalization and -3115.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CGEN vs MCRB Key Questions & Quantitative Answers

As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Seres Therapeutics, Inc. (MCRB) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CGEN carries a Unified Composite Score of 47.1/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin), whereas MCRB carries 50.0/100 (HOLD) at $1.41 (10.8x Forward P/E, -3115.1% operating margin). Composite vs. Pillar Nuance: While MCRB currently prints a higher short-term Unified Composite Score (50.0/100 HOLD vs. CGEN 47.1/100 HOLD), CGEN captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (41.3% vs. -3115.1% operating margin) and revenue trajectory (+102.1% vs. +68.9% YoY). Technical & Structure Timing Caution: CGEN is currently in a Breakdown options structure phase (RSI 46.9); meanwhile MCRB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CGEN leads the Growth & Scale pillar: CGEN posts +102.1% YoY revenue growth and +0.0% YoY earnings growth on $76M TTM revenue (86.2% gross margin, 41.3% operating margin), compared with MCRB at +68.9% YoY revenue growth and -91.9% YoY earnings growth on $2.1M TTM revenue (N/A gross margin, -3115.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CGEN cumulative revenue shifted +250.0% while MCRB shifted -66.7%. In operating R&D and SG&A reinvestment, CGEN deploys 44.9% of Rev ($34M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MCRB.

CGEN screens cheaper on headline valuation multiples. CGEN trades at 12.4x Forward P/E, 5.2x Trailing P/E, 1.29x PEG, and 2.5x EV/Revenue (41.9% EBITDA margin), whereas MCRB trades at 10.8x Forward P/E, 10.8x Trailing P/E, N/M PEG, and 15.1x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CGEN (57.2% ROE) versus MCRB (-144.3% ROE) capital efficiency.

In options market volatility and institutional positioning, CGEN carries 89.7% implied volatility (57th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.44β · 62% Vol realized risk). By comparison, MCRB carries 95.5% implied volatility (22nd %ile, Compressed (<25th %ile)), a 104.33x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.68β · 92% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.